The US Food and Drug Administration has approved the first Alzheimer’s drug to slow the progression of the neurodegenerative disease, paving the way for millions of American patients to access the treatment.
The regulator said on Thursday it would grant full approval to lecanemab, now known by the brand name Leqembi, which was developed by Japanese drugmaker Eisai and US biotech Biogen.
Teresa Buracchio, acting director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research, said a confirmatory study had shown that Leqembi was a “safe and effective treatment” for patients with Alzheimer’s.
您已阅读19%（624字），剩余81%（2619字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。